NCT06699979Recruiting
Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
Comprehensive Multi-Omics Analysis of Early-Stage Lung Cancer Exhibiting Distinct Phenotypes
Source: ClinicalTrials.gov · Last updated 7 Jul 2026
Brief summary (registry, in English)
The goal of this observational study is to investigate the multi-omics characterization early-stage lung cancer exhibiting distinct phenotypes including lung cancer associated with cystic airspaces, multiple primary lung cancers, and so on. The main questions it aims to answer are: * What are the differences in pathogenesis of non-small cell lung cancer with different phenotypes explored by multi-omics? * Whether differential genes lead to potential prognostic models and therapeutic targets? Participants will be followed up after surgery to answer prognosis: whether they have recurred, and the time to recurrence.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 9 Nov 2024
- Start date
- 29 Aug 2024
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Central South University
- Diseases
- Lung cancer
- NCT number
- NCT06699979
What you commit to
- Study type: Observational
- Planned participants: 300
- From 29 Aug 2024 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- A history of previous or co-existing malignant tumors;
- Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;
- A history of previous or co-existing malignant tumors;
- Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;
Other illness
- Refusal to participate in the study.
- Cohort 2: Multi-omics study of lung cancer associated with cystic airspaces
Other
- Refusal to participate in the study.
Who the study is looking for
- Male or female patients:18-75 years old;
- ECOG score:0-1;
- Histopathologically confirmed TNM stage I-II NSCLC;
- Considered multiple or solitary primary lung cancer by clinical criteria (Martini-Melamed criteria and ACCP criteria);
- Good compliance, family members agree to cooperate to receive survival follow-up;
- Understand and voluntarily sign the informed consent.
- Male or female patients:18-75 years old;
- ECOG score:0-1;
- Histopathologically confirmed TNM stage I-II NSCLC;
- CT findings show solitary or multiple nodules with cystic airspaces.
Criteria the registry did not label
- Cohort 1: Multi-omics study in early-stage synchronous multiple primary lung cancer
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Second Xiangya Hospital of Central South University Coordinator of this site? Confirm its status | Changsha | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.